3V Medical Research Group
3V Medical Research Group is dedicated to developing safe and effective medical products for common, debilitating conditions. They focus on treatments based on simple molecules and well-understood drug delivery mechanisms, with a strong commitment to safety through well-designed clinical studies. Their mission is to create treatments that improve quality of life for many people.
Industries
Nr. of Employees
small (1-50)
3V Medical Research Group
1330 Old Freeport Road, 1B, Pittsburgh, PA 15238
Products
Luxsol
A nebulized suspension formulated for targeted delivery to the lungs intended for treatment of respiratory illness associated with SARS-CoV-2 and influenza; reported in vitro antiviral activity and covered by a US patent (US Patent No. 11,000,545).
Ostrolux
A topical cream evaluated in a small clinical study for management of osteoarthritis knee pain and for reduction of radiation dermatitis discomfort; reported improvements in VAS pain scores and patient-rated disease severity in a per-protocol population, with rare and mild adverse events reported in the study.
Luxsol
A nebulized suspension formulated for targeted delivery to the lungs intended for treatment of respiratory illness associated with SARS-CoV-2 and influenza; reported in vitro antiviral activity and covered by a US patent (US Patent No. 11,000,545).
Ostrolux
A topical cream evaluated in a small clinical study for management of osteoarthritis knee pain and for reduction of radiation dermatitis discomfort; reported improvements in VAS pain scores and patient-rated disease severity in a per-protocol population, with rare and mild adverse events reported in the study.
Services
Design of clinical protocols, management of clinical studies across sites, and safety monitoring services for investigational therapeutics.
Execution of in vitro antiviral studies against respiratory viruses using partnered high-containment laboratory facilities.
Consultative support for development activities related to GMP manufacturing for clinical supply.
Advisory interactions with regulatory consultants, CROs, and regulatory authorities; support for business development and IP strategy.
Design of clinical protocols, management of clinical studies across sites, and safety monitoring services for investigational therapeutics.
Execution of in vitro antiviral studies against respiratory viruses using partnered high-containment laboratory facilities.
Consultative support for development activities related to GMP manufacturing for clinical supply.
Advisory interactions with regulatory consultants, CROs, and regulatory authorities; support for business development and IP strategy.
Expertise Areas
- Clinical trial management
- Targeted pulmonary drug delivery
- Topical therapeutics for pain management
- Preclinical antiviral testing
Key Technologies
- Nebulized/aerosol pulmonary delivery
- Topical cream formulation
- In vitro antiviral cytotoxicity and viral kill assays
- BSL-3/BSL-4 high-containment testing
News & Updates
Luxsol™ is covered by a patent granted by the USPTO to treat Covid-19 virus and Influenza, US Patent No. 11,000,545 on May 11, 2021.
Luxsol™ is covered by a patent granted by the USPTO to treat Covid-19 virus and Influenza, US Patent No. 11,000,545 on May 11, 2021.